PEGylated Protein Therapeutics Market Analysis, and Insights to Improve R&D Strategies 2025


Posted March 15, 2019 by sandeeps88

Surge in prevalence of chronic diseases across the globe is anticipated to significantly drive the growth of the PEGylated protein therapeutics market.
 
PEGylation is a process of addition of active polyethylene glycol (PEG) to different forms of therapeutic proteins for chemical modification. These chemically modified therapeutic proteins are called PEGylated protein therapeutics. The chemical modification due to PEGylation results in various advantages, such as an extended half-life of a drug along with low toxicity and increased proteolytic protection, over the non-modified protein therapeutics.

PEGylated protein therapeutics are used in multiple conditions such as cancer, hemophilia, rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, and others.

Download sample copy @ https://www.alliedmarketresearch.com/request-sample/3726

According to a new report published by Allied Market Research, titled, " PEGylated Protein Therapeutics Market by Product Type, Application, and Sales Channel: Global Opportunity Analysis and Industry Forecast, 2018-2025, the market was valued at $10,388 million in 2017, and is projected to reach $17,813 million by 2025, growing at a CAGR of 6.9% from 2018 to 2025. North America is anticipated to be the highest revenue contributor throughout the forecast period.

Major Players:

• Amgen Inc.
• AstraZeneca PLC
• Biogen Inc.
• F. Hoffmann-La Roche Ltd. (Genentech Inc.)
• Horizon Pharma plc.
• Leadiant Biosciences S.p.A.
• Merck & Co.Inc. (Schering-Plough Corporation)
• Pfizer Inc.
• Shire plc (Baxalta)
• UCB S.A.

The factors that drive the growth of the global PEGylated protein therapeutics market are an increase in prevalence of chronic diseases, advantages offered by PEGylation, and strong presence of pipeline drugs are. However, high cost related to drug development and launch of generics during the forecast period is expected to impede the market growth.

In addition, high market potential in the untapped emerging economies and increase in adoption of PEGylated protein therapeutics are expected to provide many opportunities during the forecast period.

Key Benefits for Stakeholders:

• This report entails a detailed quantitative analysis of the current market trends from 2017 to 2025 to identify the prevailing opportunities along with the strategic assessment of global PEGylated protein therapeutics market.

• Market size and estimations are based on a comprehensive analysis of the applications and developments in the industry.

• A qualitative analysis based on innovative products facilitates strategic business planning.

• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the PEGylated protein therapeutics industry.


Send enquiry us @ https://www.alliedmarketresearch.com/purchase-enquiry/3726

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.
Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Allied Market Research
Country United States
Categories Industry , Medical , Research
Tags pegylated protein therapeutics market
Last Updated March 15, 2019